HIV aspartic peptidase inhibitors are effective drugs against the trypomastigote form of the human pathogen Trypanosoma cruzi
- PMID: 27499433
- DOI: 10.1016/j.ijantimicag.2016.06.024
HIV aspartic peptidase inhibitors are effective drugs against the trypomastigote form of the human pathogen Trypanosoma cruzi
Abstract
There is a general lack of effective and non-toxic chemotherapeutic agents against Chagas' disease despite more than a century of research. In this regard, we have verified the impact of human immunodeficiency virus aspartic peptidase inhibitors (HIV-PIs) on the viability and morphology of infective trypomastigote forms of Trypanosoma cruzi as well as on the aspartic peptidase and proteasome activities produced by this parasite. The effects of HIV-PIs on viability were assessed by counting motile parasites in a Neubauer chamber. Morphological alterations were detected by light microscopy of Giemsa-stained smears and scanning electron microscopy. Modulation of aspartic peptidase and proteasome activities by the HIV-PIs was measured by cleavage of fluorogenic peptide substrates. The majority of the HIV-PIs (6/9) were able to drastically decrease the viability of trypomastigotes after 4 h of treatment, with nelfinavir and lopinavir being the most effective compounds presenting LD50 values of 8.6 µM and 10.6 µM, respectively. Additionally, both HIV-PIs were demonstrated to be effective in a time- and cell density-dependent manner. Treatment with nelfinavir and lopinavir caused many morphological/ultrastructural alterations in trypomastigotes; parasites became round in shape, with reduced cell size and flagellar shortening. Nelfinavir and lopinavir were also capable of significantly inhibiting the aspartic peptidase and proteasome activities measured in trypomastigote extracts. These results strengthen the data on the positive effects of HIV-PIs on parasitic infections, possibly by targeting the parasite aspartic peptidase(s) and proteasome(s), opening a new possibility for the use of these clinically approved drugs as an alternative chemotherapy to treat Chagas' disease.
Keywords: Aspartic peptidase; HIV peptidase inhibitor; Morphological alterations; Proteasome; Trypanosoma cruzi.
Copyright © 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
Similar articles
-
Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.PLoS One. 2014 Dec 2;9(12):e113957. doi: 10.1371/journal.pone.0113957. eCollection 2014. PLoS One. 2014. PMID: 25464510 Free PMC article.
-
Primary evidence of the mechanisms of action of HIV aspartyl peptidase inhibitors on Trypanosoma cruzi trypomastigote forms.Int J Antimicrob Agents. 2018 Aug;52(2):185-194. doi: 10.1016/j.ijantimicag.2018.03.021. Epub 2018 Apr 7. Int J Antimicrob Agents. 2018. PMID: 29635008
-
Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells and show anti-amastigote activity.Int J Antimicrob Agents. 2016 Dec;48(6):703-711. doi: 10.1016/j.ijantimicag.2016.09.017. Epub 2016 Oct 31. Int J Antimicrob Agents. 2016. PMID: 27838277
-
The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi.Curr Top Med Chem. 2017;17(11):1303-1317. doi: 10.2174/1568026616666161025161153. Curr Top Med Chem. 2017. PMID: 27784256 Review.
-
Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.Curr Med Chem. 2013;20(25):3116-33. doi: 10.2174/0929867311320250007. Curr Med Chem. 2013. PMID: 23298141 Free PMC article. Review.
Cited by
-
Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors.Mem Inst Oswaldo Cruz. 2022 Mar 16;117:e210386. doi: 10.1590/0074-02760210386. eCollection 2022. Mem Inst Oswaldo Cruz. 2022. PMID: 35293428 Free PMC article.
-
Tropical Parasitic Infections in Individuals Infected with HIV.Curr Trop Med Rep. 2017 Dec;4(4):268-280. doi: 10.1007/s40475-017-0130-6. Epub 2017 Oct 16. Curr Trop Med Rep. 2017. PMID: 33842194 Free PMC article.
-
Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069.PLoS Negl Trop Dis. 2020 Jan 21;14(1):e0007481. doi: 10.1371/journal.pntd.0007481. eCollection 2020 Jan. PLoS Negl Trop Dis. 2020. PMID: 31961864 Free PMC article.
-
Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase.BMC Res Notes. 2018 Nov 21;11(1):825. doi: 10.1186/s13104-018-3927-z. BMC Res Notes. 2018. PMID: 30463602 Free PMC article.
-
Extracellular vesicles and vesicle-free secretome of the protozoa Acanthamoeba castellanii under homeostasis and nutritional stress and their damaging potential to host cells.Virulence. 2018 Dec 31;9(1):818-836. doi: 10.1080/21505594.2018.1451184. Virulence. 2018. PMID: 29560793 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials